Tafasitamab
As of the edition of 20 October 2026, Tafasitamab is an antibody: marketed, first approved in 2020 (US); acts on CD19; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Monjuvi
- First approved
- 31 July 2020 (US)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Incyte Biosciences Japan G.K.; 3 holders in all
- Registered trials
- 54, 8 stopped early
- Disease areas
- Blood and lymph; Immune system; Cancer; Infections; Lungs and airways; Digestive system
US protection
US protection ends in 2032.
US protection ends in 2032, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Incyte. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Tafasitamab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD19 | B-lymphocyte antigen CD19 | P15391 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 1 | 6 | 2 | 3 | 0 |
| Phase 2 | 40 | 4 | 28 | 8 |
| Phase 3 | 5 | 1 | 4 | 0 |
| All trials | 54 |